BridgeMD
New treatment option for Overweight
Official title A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
ClinicalTrials.gov ID: NCT07395687
What this study is testing
What is UBT251?
UBT251 is an investigational medicine, given as an injection under the skin, being studied as a potential treatment for overweight.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this clinical study is to find out if UBT251 is safe and effective for treating people who are living with overweight or obesity. Participants will get either UBT251 (the treatment being tested) or Placebo (a treatment that has no active medicine in it), which treatment participants get is decided by chance.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Male or female (sex at birth).
- For Part C: Japanese, Chinese or non-Asian participants (all self-reported):
- For Japanese participants: both parents of Japanese descent.
- For Chinese participants: both parents of Chinese descent.
- For non-Asian participants: both parents of non-Asian descent (non-Asian is defined as of countries outside of Asia).
You likely can't join if
- Known or suspected hypersensitivity to study intervention(s) or related products.
- Treatment with any marketed product containing compounds with glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) or...
- Any condition, unwillingness or inability, which in the investigator's opinion might jeopardise the participant's safety or compliance with the...
See the full eligibility criteria
- Male or female (sex at birth).
- For Part C: Japanese, Chinese or non-Asian participants (all self-reported):
- For Japanese participants: both parents of Japanese descent.
- For Chinese participants: both parents of Chinese descent.
- For non-Asian participants: both parents of non-Asian descent (non-Asian is defined as of countries outside of Asia).
- Age at the time of signing the informed consent:
- For Part A: 18-55 years (both inclusive)
- For Part B: 18-65 years (both inclusive)
- For Part C: 18-55 years (both inclusive).
- BMI at screening (overweight and obesity should be due to excess adipose tissue, as judged by the investigator):
- For Part A: 27.0-39.9 kilogram per meter square (kg/m\^2) (both inclusive)
- For Part B: 30.0-50.0 kg/m\^2 (both inclusive)
- For Part C: 24-34.9 kg/m\^2 (both inclusive)
- Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG), and clinical laboratory tests performed during the screening visit, as judged by the...
- Known or suspected hypersensitivity to study intervention(s) or related products.
- Treatment with any marketed product containing compounds with glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) or glucagon receptor agonism within 90 days before screening.
- Any condition, unwillingness or inability, which in the investigator's opinion might jeopardise the participant's safety or compliance with the protocol.
The study team makes the final eligibility decision.
Where it's taking place
- Cypress, California, United States
- Overland Park, Kansas, United States
- Montreal, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Cypress, California, United States; Overland Park, Kansas, United States; Montreal, Quebec, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.